HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
HCW Biologics (NASDAQ: HCWB) announced that its Founder and CEO, Hing C. Wong, Ph.D., will participate as a panelist at the 2025 GenScript Biotech Global Forum during J.P. Morgan Week in San Francisco. The panel discussion, focusing on Cell and Gene Therapy (CGT) challenges in biomanufacturing and supply chain management, will take place on January 15, 2025.
The company has developed subcutaneous immunotherapeutics using its drug discovery platform, categorized into three classes: Multi-Functional Immune Cell Stimulators, Second-Generation Immune Checkpoint Inhibitors and Multi-Specific Targeting Fusions, and Enhanced Immune-Cell Engagers. Dr. Wong will discuss how combining CGTs with their proprietary molecules could reduce costs and improve clinical efficacy of engineered effector cells. He will also present why Immune-Cell Engagers could potentially challenge cell-based therapies for cancer, autoimmune diseases, and aging-related conditions.
HCW Biologics (NASDAQ: HCWB) ha annunciato che il suo fondatore e CEO, Hing C. Wong, Ph.D., parteciperà come relatore a un panel del GenScript Biotech Global Forum durante la settimana di J.P. Morgan a San Francisco. La discussione del panel, che si concentrerà sulle sfide della terapia cellulare e genica (CGT) nella biomanifattura e nella gestione della catena di approvvigionamento, si terrà il 15 gennaio 2025.
L'azienda ha sviluppato immunoterapeutiche sottocutanee utilizzando la sua piattaforma di scoperta di farmaci, categorizzata in tre classi: Stimolatori delle Cellule Immunitarie Multi-Funzionali, Inibitori del Punto di Controllo Immunitario di Seconda Generazione e Fusioni Multi-Specifiche, e Potenziatori delle Cellule Immunitarie. Il Dr. Wong discuterà di come la combinazione delle CGT con le loro molecole proprietarie potrebbe ridurre i costi e migliorare l'efficacia clinica delle cellule effettori ingegnerizzate. Presenterà inoltre perché i Potenziatori delle Cellule Immunitarie potrebbero potenzialmente sfidare le terapie basate sulle cellule per il cancro, le malattie autoimmuni e le condizioni legate all'invecchiamento.
HCW Biologics (NASDAQ: HCWB) anunció que su fundador y CEO, Hing C. Wong, Ph.D., participará como panelista en el GenScript Biotech Global Forum durante la semana de J.P. Morgan en San Francisco. La discusión del panel, que se centrará en los desafíos de la terapia celular y génica (CGT) en la biomanufactura y la gestión de la cadena de suministro, tendrá lugar el 15 de enero de 2025.
La empresa ha desarrollado inmunoterapias subcutáneas utilizando su plataforma de descubrimiento de medicamentos, categorizada en tres clases: Estimuladores Celulares Inmunitarios Multifuncionales, Inhibidores de Punto de Control Inmunitarios de Segunda Generación y Fusiones de Dianas Multiespecíficas, y Engagers de Células Inmunitarias Potenciadas. El Dr. Wong discutirá cómo la combinación de las CGT con sus moléculas patentadas podría reducir costos y mejorar la eficacia clínica de las células efectoras ingenierizadas. También presentará por qué los Engagers de Células Inmunitarias podrían desafiar potencialmente a las terapias basadas en células para el cáncer, las enfermedades autoinmunitarias y las condiciones relacionadas con la edad.
HCW Biologics (NASDAQ: HCWB)는 창립자이자 CEO인 Hing C. Wong, Ph.D.가 샌프란시스코에서 열리는 J.P. Morgan 주간 동안 GenScript Biotech Global Forum의 패널리스트로 참여할 것이라고 발표했습니다. 이 패널 토론은 생물 제조와 공급망 관리에서 세포 및 유전자 요법 (CGT)의 도전에 초점을 맞추어 2025년 1월 15일에 열릴 예정입니다.
회사는 세 가지 클래스(다기능 면역 세포 자극제, 2세대 면역 체크포인트 억제제 및 다중 특이적 타겟 융합물, 강화된 면역 세포 참여자)를 사용하여 피하 면역 치료제를 개발했습니다. Dr. Wong은 CGT와 자사 특허 분자의 결합이 어떻게 비용을 줄이고 조작된 효과 세포의 임상 효능을 개선할 수 있는지에 대해 논의할 것입니다. 또한 면역 세포 참가자가 암, 자가 면역 질환 및 노화 관련 질환에 대한 세포 기반 치료에 도전할 수 있는 이유를 발표할 것입니다.
HCW Biologics (NASDAQ: HCWB) a annoncé que son fondateur et PDG, Hing C. Wong, Ph.D., participera en tant que panéliste au GenScript Biotech Global Forum pendant la semaine J.P. Morgan à San Francisco. La discussion du panel, qui se concentrera sur les défis de la thérapie cellulaire et génique (CGT) dans la biomanufacture et la gestion de la chaîne d'approvisionnement, se déroulera le 15 janvier 2025.
L'entreprise a développé des immunothérapies sous-cutanées en utilisant sa plateforme de découverte de médicaments, classées en trois catégories : Stimulateurs de Cellules Immunitaires Multifonctionnels, Inhibiteurs de Points de Contrôle Immunitaires de Seconde Génération et Fusions Multi-Spécifiques, et Engageurs de Cellules Immunitaires Améliorés. Le Dr Wong discutera de la façon dont la combinaison des CGT avec leurs molécules propriétaires pourrait réduire les coûts et améliorer l'efficacité clinique des cellules effectrices ingénierisées. Il présentera également pourquoi les Engageurs de Cellules Immunitaires pourraient potentiellement défier les thérapies basées sur les cellules pour le cancer, les maladies auto-immunes et les affections liées au vieillissement.
HCW Biologics (NASDAQ: HCWB) gab bekannt, dass der Gründer und CEO, Hing C. Wong, Ph.D., als Panelist beim GenScript Biotech Global Forum während der J.P. Morgan Woche in San Francisco teilnehmen wird. Die Podiumsdiskussion, die sich mit den Herausforderungen der Zell- und Gentherapie (CGT) in der Bioproduktion und dem Lieferkettenmanagement befasst, findet am 15. Januar 2025 statt.
Das Unternehmen hat subkutane Immuntherapeutika entwickelt, die in drei Klassen eingeteilt sind: Multifunktionale Immunzellstimulatoren, Zweite Generation Immun-Checkpoint-Inhibitoren und Multi-spezifische Ziel-Fusionen sowie Verstärker von Immunzellen. Dr. Wong wird erörtern, wie die Kombination von CGTs mit ihren proprietären Molekülen die Kosten senken und die klinische Wirksamkeit von gentechnisch veränderten Effektor-Zellen verbessern könnte. Er wird auch erläutern, warum Immunzellverstärker potenziell zellbasierte Therapien gegen Krebs, Autoimmunerkrankungen und altersbedingte Bedingungen herausfordern könnten.
- None.
- None.
Invited Speaker at 2025 GenScript Biotech Global Forum
MIRAMAR, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic inflammation and disease, announced today that Hing C. Wong, PhD., Founder and CEO, will serve as a panelist on Panel Discussion II of the 2025 GenScript Biotech Global Forum as a thought leader regarding Conquering Cell and Gene Therapy (“CGT”) Challenges in Biomanufacturing and Supply Chain Management. The event is taking place on January 15, 2025, alongside the 2025 J.P. Morgan Healthcare Conference in San Francisco.
Details are as follows:
| Event: | 2025 GenScript Biotech Global Forum |
| Panelist: | Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics Inc. |
| Panel Discussion II: | Conquering CGT’s Challenges in Biomanufacturing and Supply Chain Management |
| Time: | 4:05 PM - 5:00 PM PT, January 15, 2025 |
| Location: | San Francisco Marriott Marquis, CA (In-person/Livestream) |
| Event website: | https://genscript-global-biotech-forum.cventevents.com/event/0027fbb0-b171-4f52-bcd9-ba57c357928e/home |
HCWB has developed immunotherapeutics administered by subcutaneous injection with its new drug discovery platform technology which the Company categorizes into three classes (https://hcwbiologics.com/technology/). In each of these classes, the Company has created molecules for potential treatment of hematologic and solid tumors, virally infected cells, and cellular senescence diseases associated with aging. Class I is Multi-Functional Immune Cell Stimulators; Class II is Second-Generation Immune Checkpoint Inhibitors and Multi-Specific Targeting Fusions; and Class III is Enhanced Immune-Cell Engagers.
One of the greatest challenges for CGT is the cost of manufacturing, which can make them inaccessible to many patients. During the panel discussion, Dr. Wong will describe how utilizing CGTs in combination with some of the proprietary molecules the Company has constructed with its new drug discovery platform could potentially benefit CGT by significantly reducing costs and improving the clinical efficacy of engineered effector cells for CGT. In addition, Dr. Wong will discuss why he believes that Immune-Cell Engagers, which include the T-Cell Engagers and NK-Cell Engagers created by HCW Biologics, could effectively challenge cell-based therapies as optimal treatment for cancer, autoimmune diseases, and aging related indications.
About HCW Biologics:
HCW Biologics is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular, diabetes, neurodegenerative, and autoimmune diseases, as well as other inflammatory conditions. The Company has combined a deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop two drug discovery platforms, each with a novel backbone which is used to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. The Company’s legacy drug discovery platform is its TOBI™ (Tissue factOr-Based fusIon) discovery platform, which has a Tissue-Factor based backbone. It was used to create HCW Biologics’ molecules: HCW9218, HCW9302, HCW9206 and HCW9201. The Company’s second drug discovery platform uses a unique protein-based backbone differentiated from Tissue Factor. Immunotherapeutics created with the Company’s two distinct drug discovery platforms have different characteristics and mechanisms of action, expanding the various pathways for treating senescence-associated disorders.
About GenScript Biotech Global Forum:
Gene and cell therapy is booming worldwide, fueled by major innovations in life science and medicine and funding from global capital markets. To advance this crucial field, GenScript convenes top scientists and industry leaders from around the world, concurrent with the annual JP Morgan Healthcare Conference. The upcoming GenScript Biotech Global Forum 2025 will take place at the San Francisco Marriott Marquis on Wednesday, January 15, 2025. Under the theme Challenges and Opportunities of Cell and Gene Therapy in the New Era, GenScript is inviting gene and cell therapy thought leaders from the research, industry, and capital communities, as well as representatives from regulatory bodies, to focus on recent developments in research, technological breakthroughs, commercialization challenges, and regulatory trends. (Event website: https://genscript-global-biotech-forum.cventevents.com/event/0027fbb0-b171-4f52-bcd9-ba57c357928e/home)
About ProBio:
ProBio is a global leader in enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation biologics and advanced therapies. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio supports its partners in optimizing drug development, accelerating time-to-market, and provides comprehensive life-cycle support. Through a collaborative and risk-sharing model, ProBio offers flexible options for licensing and co-development of new therapeutics. This enables our partners to effectively navigate the complexities of human disease with adaptable and versatile therapeutic approaches.
To learn more about ProBio services, please visit www.probiocdmo.com.
About GenScript:
GenScript Biotech Corporation accelerates innovation in healthcare and consumer goods by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to make people and nature healthier through biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,000 employees and has served more than 200,000 customers across 100 countries. Learn more at www.genscript.com.
Forward Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the Company’s ability to develop new immunotherapeutic treatments for non-oncology or oncology indications; the capabilities of the Company’s new platform and the effectiveness of new fusion proteins developed using the new platform; the ability of the Company’s proprietary molecules to reduce costs and improve the clinical efficacy of engineered effector cells for CGT. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K/A filed with the United States Securities and Exchange Commission (the “SEC”) on May 15, 2024, the latest Form 10-Q filed with the SEC on November 14, 2024, and in other filings filed from time to time with the SEC. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Company Contact:
Dr. Hing C. Wong
Founder and CEO
HCW Biologics Inc.
hingwong@hcwbiologics.com
FAQ
What are the three classes of immunotherapeutics developed by HCWB?
How does HCWB plan to address the cost challenges in Cell and Gene Therapy (CGT)?
What therapeutic areas is HCWB targeting with their immunotherapeutics?
When and where will HCWB's CEO present at the 2025 GenScript Biotech Global Forum?
